University of North Texas Health Science Center · PharmacologySkp2 Targeting Therapeutics Lab
Hong-Yu Li · Fort Worth, Texas
Research Focus
Dr. Hong-Yu Li's research at the University of Texas Health Science Center focuses on developing new drugs to target a protein called Skp2, which plays a significant role in cancer progression, particularly in prostate cancer. His lab is working on innovative drug candidates known as PROTACs that can effectively degrade Skp2 in cancer cells, potentially leading to improved treatments for patients with aggressive prostate cancer. By leveraging novel methods for drug development, the lab aims to bring new therapeutic options to clinical trials.
Skp2PROTACcancer therapyprostate cancerdrug development
Research Aims
5AIM 01Develop potent Skp2 PROTACs for cancer treatment.
AIM 02Evaluate pharmacokinetic properties of Skp2 PROTACs.
AIM 03Test efficacy of Skp2 PROTACs in advanced prostate cancer models.
AIM 04Identify clinical candidates for phase I trials.
AIM 05Advance drug candidates through IND enabling studies.
Skills the Lab Values
cell culturein vivo modelingdrug kinetic studiesbiological assaysxenograft models